[Alpha Biz=(Chicago) Reporter Paul Lee] It has been confirmed that Samsung Biologics is undergoing a major reorganization on the 26th. It seems that the company is focusing on slimming down its organization, with its existing positions removed, leader-level personnel demoted to team members, and parts where leaders have been dismissed are integrated.
The number of legal team members is said to have been cut in half. However, a Samsung Biologics official said, "The legal team is not in half, some have left, and some have entered the team," adding, "It is difficult to elaborate on the composition and size of the team."
In particular, James Park, vice president who was in charge of a key position as head of the Global Sales Center, quietly resigned last month. John Lim is currently concurrently serving as CEO of the company.
Vice President James Park's retirement is said to have had a significant impact internally within Samsung BioLogics. Analysts say that the resignation of Vice President James Park, who has been known the Samsung BioLogics brand on behalf of the company, is sudden. In fact, Vice President James Park attended the "2022 International Pharmaceutical Exhibition (CPHI 2022)" in Germany in early November last year, a month before he left the company. On behalf of Samsung Biologics, he actively engaged in activities such as actively discussing drug consignment development (CDMO) with global pharmaceutical companies.
With the resignation of key executives and the reorganization of leadership-level personnel, there are even voices of concern among employees about job cuts. In fact, many team and part leaders have resigned from their posts, and the possibility of further reorganization seems to be open. It is said that the slogan of management, which emphasized cost-cutting efforts this year, is recognized among employees as a reduction in labor costs.
Alphabiz Reporter Paul Lee(hoondork@alphabiz.co.kr)
